Richard Haynes

DM, MRCP

Associate Professor

MRC Project Leader Track
MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis

Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he now works on randomized trials and epidemiology (particularly in renal medicine and cardiovascular disease) at CTSU.

Recent publications

PCSK9 inhibition: ready for prime time in CKD?
Journal article

Mafham M. and Haynes R., (2018), Kidney Int, 93, 1267 - 1269
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.
Journal article

Herrington W. et al, (2018), Kidney International
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.
Journal article

Parish S. et al, (2018), Circ Genom Precis Med, 11
The Role of Lipoprotein(a) in Chronic Kidney Disease.
Journal article

Hopewell JC. et al, (2018), Journal of lipid research
ELECTIVE CONVERSION TO SIROLIMUS VS. CONTINUED TACROLIMUS IN KIDNEY TRANSPLANTATION (THE 3C STUDY): RESULTS OF A RANDOMIZED TRIAL
Journal article

Haynes R. et al, (2017), TRANSPLANT INTERNATIONAL, 30, 63 - 64

More publications